Setmelanotide
Setmelanotide has been studied in 23 papers since 2021: 1 trial and 5 observational studies in people, 1 in animals, 15 reviews; 9 in the past year. It is an approved medicine. The newest paper, Nov 2, 2026: “Weight-Loss-Enriched Reverse Cardiac Remodeling After Semaglutide and Tirzepatide Initiation on Longitudinal Echocardiography”.
1 new paper in 30 daysSee all 23 papers on setmelanotide
At a glance
The findings reach people, from one lab or study. 3 independent labs in 2 countries; 24 trials, none about aging, 3 with no results posted.
“The overall mean (SD) change in MetS-Z-BMI score after ∼1 year of treatment was -1.05 (0.88).”
None of its findings points the other way.
- 3 independent labs in 2 countries
- 24 trials, none about aging, 3 with no results posted
- Funders: Danish Diabetes Academy and 7 more
- 2 of 5 findings with company ties
- 22 of 24 trials sponsored by its developers
- Human trial1
- Humans5
- Animals1
Studies in people
1 study gave setmelanotide to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases MetS-Z-BMI scoreMean change -1.05 (SD 0.88) | Trialapproximately 1 year | 18 peoplePOMC or LEPR deficiency | The Journal of clinical endocrinology and metabolism, Oct 19, 2026 |
What did studies of setmelanotide find?
5Studies of setmelanotide measured 5 outcomes, among them MetS-Z-BMI score, HOMA-IR and liver stiffness.
MetS-Z-BMI score
downin humans1
1 study
MetS-Z-BMI score
downin humans1
Setmelanotide decreases MetS-Z-BMI score in humans (POMC or LEPR deficiency) (Mean change -1.05 (SD 0.88)).
Human trialPOMC or LEPR deficiencyapproximately 1 yearn = 18
HOMA-IR
downin humans1
1 study
HOMA-IR
downin humans1
Setmelanotide decreases HOMA-IR in humans (Bardet-Biedl syndrome).
Human trialBardet-Biedl syndrome12 monthsmalesn = 1
Liver stiffness
downin humans1
1 study
Liver stiffness
downin humans1
Setmelanotide decreases liver stiffness in humans (Bardet-Biedl syndrome).
Human trialBardet-Biedl syndrome12 monthsmalesn = 1
Body weight
downin humans1−11%
1 study
Body weight
downin humans1−11%
Setmelanotide decreases body weight in humans (Bardet-Biedl syndrome) (-10.5%).
Human trialBardet-Biedl syndrome12 monthsmalesn = 1
Weight loss
no changein mice1
1 study
Weight loss
no changein mice1
Setmelanotide showed no clear effect on weight loss in mice with calorie restriction lead-in.
Animalswith calorie restriction lead-in7 or 14 days
Has setmelanotide been tested in people?
0 of 24 about agingYes: 1 trial and 5 observational studies in people have been published, and 22 trials are registered.
Approved
Nov 25, 2020Bardet-Biedl Syndrome, acquired hypothalamic obesity, monogenic obesity, excess body weight, leptin receptor deficiency
Jul 16, 2021Obesity, Bardet-Biedl Syndrome, acquired hypothalamic obesity, treatment of obesity, leptin receptor deficiency, hunger
Repurposing
Phase 4Recruiting5 trials
Phase 4Recruiting2 trials
Phase 3Results posted1 trial
Phase 2Results posted1 trial
Phase 2Completed1 trial
Phase 2Results posted2 trials
All 7Fewer
In trials
Sexual Infantilism
Phase 3Completed4 trials
Proopiomelanocortin Deficiency
Phase 3Results posted2 trials
Optic nerve hypoplasia
Phase 3Recruiting1 trial
Septo optic dysplasia
Phase 3Recruiting1 trial
Genetic obesity
Phase 2Results posted1 trial
Smith magenis syndrome
Phase 2Results posted1 trial
Readouts due
- Mar 13, 2027
Who is developing setmelanotide?
1 company: Rhythm Pharmaceuticals.
- Companies
- Rhythm PharmaceuticalsPhase 4obesity, genetic obesity
Trial sponsors
Company19 trialsPhase 41,461 people
Charite University, Berlin, Germany
1 trialPhase 210 people
Massachusetts General Hospital
1 trialPhase 21 person